Furthermore, research has found that long-term administration of trastuzumab + pertuzumab + buparlisib (PI3K inhibitors) in combined-use treatment results in buparlisib-resistant tumors in HER2/PIK3CA H1047R transgenic mice with BC [162, 163]. Here, ERBB2 is linked to breast cancer.